Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer

  • STATUS
    Recruiting
  • participants needed
    80
  • sponsor
    Zhejiang Cancer Hospital
Updated on 25 May 2022
measurable disease
carcinoma
antivirals
metastasis
neutrophil count
liver metastasis
gemcitabine
cholangiocarcinoma
metastatic biliary tract carcinoma
cisplatin/gemcitabine
gallbladder carcinoma
intrahepatic bile duct carcinoma
biliary tract cancer

Summary

To evaluate the efficacy and safety of Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin Compared With Gemcitabine +Cisplatin as First-line Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer

Description

Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and c-Kit kinase.It is a randomized, controlled, multicenter phase II clinical trial conducted in China, and plan to recruit 80 patients who were primarily diagnosed with unresectable or metastatic biliary tract cancer who have not received previous systemic treatment.To evaluate the efficacy and safety of Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin Compared With Gemcitabine +Cisplatin as First-line Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.

Details
Condition Biliary neoplasm, Biliary Tract Cancer, Urothelial Tract Cancer, Urothelial Tract Cancer, Biliary Tract Cancer, biliary cancer
Treatment Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin, Gemcitabine Plus(+)Cisplatin
Clinical Study IdentifierNCT04300959
SponsorZhejiang Cancer Hospital
Last Modified on25 May 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note